Clicky

Novartis Ag Basl(NVSEF)

Description: Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The company's Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; and Conatus Pharmaceuticals Inc. The company was founded in 1895 and is headquartered in Basel, Switzerland.


Keywords: Medicine Biotechnology Pain Surgery Immunology Antibiotics Active Pharmaceutical Ingredients Healthcare Products Healthcare Providers Ophthalmology Neuroscience Disposable Products Dermatology Glaucoma Lenses Ophthalmic Disposable Product Metabolism Dysfunction Biosimilar Allergies Retina Contact Lens Coma Dosage Form Hepatology Ophthalmic Products Pharmaceutical Ingredients Surgeries Active Pharmaceutical Ingredient Ibm A Therapeutic Active Ingredients Contact Lenses Intraocular Lens Surgical Equipment Meli Myer Berkeley Itching Medicine Products Osage Diagnostic Devices Mge Surgical Solutions Therapeutic Device Cona Biotechnology Based Products Eye Drop Markets Healthcare Products Melinda Gates Foundation Ocular Itching Biotechnology Manufacturing Services Hormonal Therapy Meibomian Gland Dysfunction Ocular Health Products

Home Page: www.novartis.com

Lichtstrasse 35
Basel, 4056
Switzerland
Phone: 41 61 324 1111


Officers

Name Title
Dr. Vasant Narasimhan Chief Exec. Officer
Mr. Harry Kirsch Chief Financial Officer
Dr. Klaus Moosmayer Ph.D. Chief Ethics, Risk & Compliance Officer
Ms. Karen L. Hale Chief Legal Officer
Dr. Robert Kowalski Pharm.D. Chief People & Organization Officer
Mr. Steffen Lang Ph.D. Pres of Operations
Ms. Marie-France Tschudin Pres of Innovative Medicines International & Chief Commercial Officer
Mr. Richard Saynor Chief Exec. Officer of Sandoz
Paul Penepent Head of Group Financial Reporting and Accounting
Dr. Samir Shah M.D. Global Head of Investor Relations

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 14.2857
Trailing PE: 9.3247
Price-to-Book MRQ: 3.2152
Price-to-Sales TTM: 3.8151
IPO Date:
Fiscal Year End: December
Full Time Employees: 108000
Back to stocks